Prosecution Insights
Prosecution Insights
10 pending office actions • 10 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 3 (30%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.7% | +25.5% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.8% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.0% |
| WALKER, OLIVIA | 1 | 36.4% | +77.8% |
| HOPKINS, SAMANTHA LAKE | 1 | 55.3% | +63.4% |
| SIFFORD, JEFFREY MARK | 1 | 55.7% | +32.1% |
| PRAGANI, RAJAN | 1 | 50.0% | +72.5% |
| CREWS, JARET JAMES | 1 | 43.5% | +73.8% |
| HOFFPAUIR, ANDREW ELI | 1 | 41.8% | +50.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 63d |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 104d overdue |
| 17254737 | FORCE SENSING DEVICE, MEDICAL ENDODEVICE AND PROCESS OF USING SUCH ENDODEVICE | HOFFPAUIR, ANDREW ELI | 60d overdue |
| 18526732 | TREATMENT OF NEUROLOGICAL DISORDERS | HOWELL, THEODORE R | 28d |
| 18554473 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | ANDERSON, REBECCA L | — |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | — |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1626 | 1 |
| 1672 | 1 |
| 1644 | 1 |
| 3796 | 1 |
| 1641 | 1 |
| 1671 | 1 |
| 1614 | 1 |
| 1691 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18526732 | TREATMENT OF NEUROLOGICAL DISORDERS | HOWELL, THEODORE R | 1628 | §112Other | Non-Final OA | 28d | Pending | Dec 01, 2023 |
| 18554473 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | ANDERSON, REBECCA L | 1626 | §112Other | Non-Final OA | — | Pending | Oct 08, 2023 |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | 63d | Pending | Sep 05, 2023 |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18251450 | ENDODEVICE | WALKER, OLIVIA | 3796 | §102§103 | Non-Final OA | — | Pending | May 02, 2023 |
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Final Rejection | 110d overdue | Pending | Feb 14, 2023 |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | 1671 | §102§103§112Other | Final Rejection | — | Pending | Apr 28, 2022 |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 1614 | §103 | Final Rejection | 104d overdue | Pending | Jan 17, 2022 |
| 17415735 | NA+/K+ ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Jun 18, 2021 |
| 17254737 | FORCE SENSING DEVICE, MEDICAL ENDODEVICE AND PROCESS OF USING SUCH ENDODEVICE | HOFFPAUIR, ANDREW ELI | 3791 | §103 | Non-Final OA | 60d overdue | Pending | Dec 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial